While BM PC bind type I IFN receptor-blocking antibody anifrolumab, it is to a lesser degree than circulating B cells. Anti-nuclear autoantibodies (ANA) are found in the BM supernatant and PBL serum ...

Opens in a new tab or window The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo ...

Uptake of belimumab continues to outpace the use of anifrolumab among clinicians managing patients with systemic lupus erythematosus, according to a survey conducted by Spherix Global Insights.

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Polymyositis. According to GlobalData, Phase III drugs for Polymyositis does not have sufficient historical data ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase III for Dermatomyositis. According to GlobalData, Phase III drugs for Dermatomyositis have a 20% phase transition ...